Osterweis Capital Management Inc. grew its position in shares of Teleflex Incorporated (NYSE:TFX) by 0.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 90,707 shares of the medical technology company’s stock after acquiring an additional 242 shares during the quarter. Osterweis Capital Management Inc. owned 0.20% of Teleflex worth $22,570,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in TFX. Aperio Group LLC boosted its position in Teleflex by 4.4% during the 3rd quarter. Aperio Group LLC now owns 13,599 shares of the medical technology company’s stock worth $3,290,000 after acquiring an additional 571 shares during the last quarter. Pictet Asset Management Ltd. boosted its holdings in shares of Teleflex by 5.3% in the 3rd quarter. Pictet Asset Management Ltd. now owns 15,170 shares of the medical technology company’s stock valued at $3,671,000 after buying an additional 770 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in shares of Teleflex in the 3rd quarter valued at approximately $1,327,000. Victory Capital Management Inc. boosted its holdings in shares of Teleflex by 15.9% in the 3rd quarter. Victory Capital Management Inc. now owns 8,488 shares of the medical technology company’s stock valued at $2,054,000 after buying an additional 1,163 shares during the last quarter. Finally, Andra AP fonden boosted its holdings in shares of Teleflex by 15.9% in the 3rd quarter. Andra AP fonden now owns 15,300 shares of the medical technology company’s stock valued at $3,702,000 after buying an additional 2,100 shares during the last quarter. 90.75% of the stock is owned by hedge funds and other institutional investors.
Teleflex Incorporated (TFX) traded down $1.66 on Wednesday, reaching $265.69. The company had a trading volume of 282,551 shares, compared to its average volume of 316,611. Teleflex Incorporated has a twelve month low of $191.04 and a twelve month high of $288.78. The company has a current ratio of 2.33, a quick ratio of 1.51 and a debt-to-equity ratio of 0.89. The company has a market cap of $12,000.22, a PE ratio of 81.76, a PEG ratio of 1.96 and a beta of 1.22.
Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The business had revenue of $595.10 million for the quarter, compared to analysts’ expectations of $601.17 million. During the same quarter in the prior year, the business earned $2.13 EPS. The firm’s revenue for the quarter was up 15.8% on a year-over-year basis. analysts predict that Teleflex Incorporated will post 9.68 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Friday, March 2nd will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.51%. The ex-dividend date is Thursday, March 1st. Teleflex’s dividend payout ratio (DPR) is presently 41.59%.
Several equities research analysts have recently commented on the company. TheStreet downgraded Teleflex from an “a-” rating to a “c+” rating in a report on Monday. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Leerink Swann reissued a “buy” rating and issued a $321.00 price objective (up previously from $307.00) on shares of Teleflex in a report on Tuesday, January 30th. Stephens reissued a “buy” rating and issued a $300.00 price objective on shares of Teleflex in a report on Thursday, January 18th. Finally, Deutsche Bank downgraded Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price objective for the company. in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $281.56.
In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $248.96, for a total transaction of $49,792.00. Following the transaction, the director now owns 8,080 shares in the company, valued at approximately $2,011,596.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP John Deren sold 1,359 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $255.67, for a total value of $347,455.53. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,259 shares of company stock worth $3,760,536. 2.39% of the stock is owned by company insiders.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.